Best Researched Peptides for Metabolic & Body-Composition Models
Incretin, amylin and mitochondrial compounds dominate metabolic-model literature. Here is what appears most often, with the specs that matter for lab handling. Specs, reported ranges and lot documentation for each compound.
By PX1 Research Team · August 4, 2026
Best Researched Peptides for Metabolic & Body-Composition Models
Incretin, amylin and mitochondrial compounds dominate metabolic-model literature. Here is what appears most often, with the specs that matter for lab handling.
| Compound | Class | Lowest reported study amount | Vial sizes |
|---|---|---|---|
| Retatrutide (GLP-3) | GIP/GLP-1/glucagon triple receptor agonist | 1 mg | 10 mg / 15 mg / 20 mg / 30 mg |
| Tirzepatide (GLP-2) | dual GIP/GLP-1 receptor agonist | 2.5 mg | 10 mg / 15 mg / 30 mg / 60 mg |
| Semaglutide | GLP-1 receptor agonist | 0.25 mg | 5 mg / 10 mg |
| Cagrilintide | long-acting amylin analog | 0.3 mg | 5 mg / 10 mg |
| Survodutide | dual glucagon/GLP-1 receptor agonist | 0.6 mg | 10 mg |
| Mazdutide | GLP-1/glucagon dual agonist | 1.5 mg | 10 mg |
| 5-Amino-1MQ | small-molecule NNMT inhibitor | 50–100 mg | 5 mg vial / 50 mg capsules |
| SLU-PP-332 | pan-ERR agonist (exercise-mimetic small molecule) | 250–500 mcg | 5 mg / 20 mg vial · 250 mcg capsules |
Compound-by-compound notes
Retatrutide (GLP-3)
Retatrutide (GLP-3) is a GIP/GLP-1/glucagon triple receptor agonist studied in metabolic and body-composition research. Standard preparation is 10 mg + 2 mL bacteriostatic water = 5 mg/mL. Reported arms:
| Study arm | Reported amount | Cadence |
|---|---|---|
| Initiation | 1 mg | weekly × 4 |
| Step 1 | 2 mg | weekly × 4 |
| Step 2 | 4 mg | weekly × 4 |
| Step 3 | 8 mg | weekly × 4 |
| Maximal arms | 12 mg | weekly |
Product page: Retatrutide (GLP-3).
Tirzepatide (GLP-2)
Tirzepatide (GLP-2) is a dual GIP/GLP-1 receptor agonist studied in incretin and metabolic research. Standard preparation is 10 mg + 2 mL = 5 mg/mL. Reported arms:
| Study arm | Reported amount | Cadence |
|---|---|---|
| Initiation | 2.5 mg | weekly × 4 |
| Step 1 | 5 mg | weekly × 4 |
| Step 2 | 7.5 mg | weekly × 4 |
| Step 3 | 10 mg | weekly × 4 |
| Maximal arms | 15 mg | weekly |
Product page: Tirzepatide (GLP-2).
Semaglutide
Semaglutide is a GLP-1 receptor agonist studied in GLP-1 receptor research. Standard preparation is 5 mg + 2 mL = 2.5 mg/mL. Reported arms:
| Study arm | Reported amount | Cadence |
|---|---|---|
| Initiation | 0.25 mg | weekly × 4 |
| Step 1 | 0.5 mg | weekly × 4 |
| Step 2 | 1 mg | weekly × 4 |
| Step 3 | 1.7 mg | weekly × 4 |
| Maximal arms | 2.4 mg | weekly |
Product page: Semaglutide.
Cagrilintide
Cagrilintide is a long-acting amylin analog studied in amylin-pathway and satiety-signalling research. Standard preparation is 10 mg + 2 mL = 5 mg/mL. Reported arms:
| Study arm | Reported amount | Cadence |
|---|---|---|
| Initiation | 0.3 mg | weekly × 4 |
| Step 1 | 0.6 mg | weekly × 4 |
| Step 2 | 1.2 mg | weekly × 4 |
| Maximal arms | 2.4 mg | weekly |
Product page: Cagrilintide.
Survodutide
Survodutide is a dual glucagon/GLP-1 receptor agonist studied in dual-agonist metabolic research. Standard preparation is 10 mg + 2 mL = 5 mg/mL. Reported arms:
| Study arm | Reported amount | Cadence |
|---|---|---|
| Initiation | 0.6 mg | weekly × 4 |
| Step 1 | 1.2 mg | weekly × 4 |
| Step 2 | 2.4 mg | weekly × 4 |
| Maximal arms | 6 mg | weekly |
Product page: Survodutide.
Mazdutide
Mazdutide is a GLP-1/glucagon dual agonist studied in oxyntomodulin-analog research. Standard preparation is 10 mg + 2 mL = 5 mg/mL. Reported arms:
| Study arm | Reported amount | Cadence |
|---|---|---|
| Initiation | 1.5 mg | weekly × 4 |
| Step 1 | 3 mg | weekly × 4 |
| Maximal arms | 6 mg | weekly |
Product page: Mazdutide.
5-Amino-1MQ
5-Amino-1MQ is a small-molecule NNMT inhibitor studied in NNMT and adipocyte-metabolism research. Standard preparation is 5 mg + 2 mL = 2.5 mg/mL. Reported arms:
| Study arm | Reported amount | Cadence |
|---|---|---|
| Oral arm | 50–100 mg | daily |
| Injectable arm | 2.5–5 mg | daily |
Product page: 5-Amino-1MQ.
SLU-PP-332
SLU-PP-332 is a pan-ERR agonist (exercise-mimetic small molecule) studied in estrogen-related-receptor and endurance research. Standard preparation is 20 mg + 4 mL = 5 mg/mL. Reported arms:
| Study arm | Reported amount | Cadence |
|---|---|---|
| Standard arm | 250–500 mcg | daily |
Product page: SLU-PP-332.
How researchers evaluate material before running anything
Purity claims mean nothing without a lot-specific COA showing an HPLC chromatogram, LC-MS identity and endotoxin results. PX1 publishes all three at /coa.
How PX1 documents every lot
Every PX1 lot ships with HPLC purity, LC-MS identity, residual solvent, moisture (Karl Fischer), sterility and endotoxin data. Lot documentation is published at /purity-reports, /endotoxin-reports and /coa. Synthesis, purification, lyophilization and vial fill happen in U.S. facilities — see /manufacturing-process.
Research use only. PX1 Research supplies compounds for laboratory and in-vitro research. Nothing here is medical advice, a dosing recommendation, or an offer for human or veterinary use. Figures cited are reported from published laboratory literature.